A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge

OXFORD, England, October 21, 2010 – In the current BioPharma economic climate; with smaller
companies desperately needing the right development partners for survival and
larger ones needing to support their existing businesses through making the
right deals, having the best, most comprehensive, intelligence and insights
are absolutely essential for success.

It is into this environment … Read more : A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge.

Mammography Clinic Takes up the Fight Against Osteoporosis

Combining Low Dose Mammography and new Online Service From Sectra
LINK??PING, Sweden, October 21, 2010 – Sectra announces an agreement with Aspen Healthcare Ltd for use of
Sectra's unique solution for mammography and osteoporosis screening at Holly
House Hospital. The hospital is the first in the UK to give women the
opportunity of better quality of life by …. Source  : Gaea News Network.

IDEV Technologies Launches Additional Products in Europe

New Sizes of SUPERA(R) Stent Expand Treatment Options for Peripheral Vascular Disease

WEBSTER, Texas, October 21, 2010 – IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced another step in the implementation of its strategy to expand
its product line for treating patients with peripheral vascular disease with
the …. Original article on Gaea Times at  : IDEV Technologies Launches Additional Products in Europe.

Protecting Women’s Health in Long-Term Partnership

LONDON, October 21, 2010 – OCS Group CEO Chris Cracknell and Conrad Mielcuszny, CEO of
Genesis Biosciences, have signed a long-term agreement continuing the
exclusive use of the ground breaking germicide Activap(TM) in Cannon Hygiene
(part of the OCS Group) feminine hygiene units. Activap(TM) is the world's
most advanced, proven effective in-use germicide for feminine hygiene waste
disposal. Results … Read more >>.

New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia

Findings From Largest MRSA Nosocomial Pneumonia Study Conducted to Date Were Presented During IDSA Annual Meeting

NEW YORK, October 21, 2010 – Results of a new international phase 4 study of patients with nosocomial
pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA)
demonstrated that the antibiotic Zyvox(R) (linezolid) achieved a
statistically significantly higher clinical success rate compared with
vancomycin …. Source article  : New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia.

The British Association of Cosmetic Doctors Launches the UK’s First Post Graduate Diploma in Cosmetic Medicine

Setting the Standard for Cosmetic Medical Treatments
LONDON, October 21, 2010 – The British Association of Cosmetic Doctors has launched the
first Post Graduate Diploma in Cosmetic Medicine specifically for doctors
through Leicester Medical School. This is the only qualification specifically
related to medical cosmetics and accredited by a medical school. With an
estimated 1 million* injectable cosmetic treatments … Read more >>>.

Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix(TM) Biliary Stents

Latest Innovation in Plastic Biliary Stent Technology Includes Features for Enhanced Deliverability, Efficiency and Procedural Control

NATICK, Massachusetts, October 21, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced that it has
received 510(k) clearance from the U.S. Food and Drug Administration and CE
Mark approval to market its Advanix(TM) Biliary Plastic Stents for the
treatment of biliary … Read the original article on Gaea Times at : Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix(TM) Biliary Stents.

Lloydspharmacy Reports Young Brits’ Blood Pressure Rising

COVENTRY, England, October 21, 2010 – Lloydspharmacy has announced the publication of a new study that reveals
35 per cent of 16-34 year olds had high blood pressure readings.

The study, which involved 8568 people over the age of 16, showed that
only one in four had an ideal or normal blood pressure …. Source article  : Lloydspharmacy Reports Young Brits' Blood Pressure Rising.